Alembic Pharmaceuticals Limited (NSE:APLLTD)
India
· Delayed Price · Currency is INR 909.65
+13.90 (1.55%)
May 14, 2025, 1:30 PM IST
Alembic Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Operating Revenue | 66,721 | 62,286 | 56,526 | 53,058 | 53,931 | Upgrade
|
| Revenue | 66,721 | 62,286 | 56,526 | 53,058 | 53,931 | Upgrade
|
| Revenue Growth (YoY) | 7.12% | 10.19% | 6.54% | -1.62% | 17.10% | Upgrade
|
| Cost of Revenue | 17,934 | 17,962 | 17,748 | 14,982 | 13,402 | Upgrade
|
| Gross Profit | 48,787 | 44,324 | 38,778 | 38,076 | 40,529 | Upgrade
|
| Selling, General & Admin | 15,623 | 14,463 | 11,691 | 11,330 | 10,512 | Upgrade
|
| Other Operating Expenses | 23,082 | 20,499 | 19,892 | 17,951 | 15,213 | Upgrade
|
| Operating Expenses | 41,491 | 37,717 | 34,401 | 32,201 | 27,561 | Upgrade
|
| Operating Income | 7,297 | 6,607 | 4,378 | 5,875 | 12,968 | Upgrade
|
| Interest Expense | -787.7 | -561.9 | -501.7 | -177.3 | -160.2 | Upgrade
|
| Interest & Investment Income | - | 20.9 | 3.3 | 17.3 | 15.8 | Upgrade
|
| Earnings From Equity Investments | 8.7 | -9.8 | -309.2 | 52.8 | 317.4 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 176.9 | -0.9 | 443.1 | 772.8 | Upgrade
|
| Other Non Operating Income (Expenses) | 425.6 | 4 | 2.4 | 0.5 | 1.7 | Upgrade
|
| EBT Excluding Unusual Items | 6,943 | 6,238 | 3,572 | 6,211 | 13,916 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 43.9 | 7.5 | 28.7 | 62.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 17 | -47 | 5.4 | 13.9 | Upgrade
|
| Other Unusual Items | 128.7 | - | - | - | - | Upgrade
|
| Pretax Income | 7,072 | 6,318 | 3,546 | 6,254 | 13,998 | Upgrade
|
| Income Tax Expense | 1,252 | 160 | 126.1 | 1,045 | 2,533 | Upgrade
|
| Earnings From Continuing Operations | 5,820 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade
|
| Minority Interest in Earnings | 14.1 | - | - | - | - | Upgrade
|
| Net Income | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade
|
| Net Income to Common | 5,834 | 6,158 | 3,420 | 5,209 | 11,465 | Upgrade
|
| Net Income Growth | -5.26% | 80.07% | -34.35% | -54.56% | 38.33% | Upgrade
|
| Shares Outstanding (Basic) | 197 | 197 | 197 | 197 | 194 | Upgrade
|
| Shares Outstanding (Diluted) | 197 | 197 | 197 | 197 | 194 | Upgrade
|
| Shares Change (YoY) | 0.00% | - | - | 1.46% | 2.77% | Upgrade
|
| EPS (Basic) | 29.68 | 31.33 | 17.40 | 26.50 | 59.18 | Upgrade
|
| EPS (Diluted) | 29.68 | 31.33 | 17.40 | 26.50 | 59.18 | Upgrade
|
| EPS Growth | -5.27% | 80.07% | -34.35% | -55.22% | 34.60% | Upgrade
|
| Free Cash Flow | -4,757 | 4,757 | 2,805 | 1,267 | 8,039 | Upgrade
|
| Free Cash Flow Per Share | -24.20 | 24.20 | 14.27 | 6.45 | 41.49 | Upgrade
|
| Dividend Per Share | 11.000 | 11.000 | 8.000 | 10.000 | 14.000 | Upgrade
|
| Dividend Growth | - | 37.50% | -20.00% | -28.57% | 100.00% | Upgrade
|
| Gross Margin | 73.12% | 71.16% | 68.60% | 71.76% | 75.15% | Upgrade
|
| Operating Margin | 10.94% | 10.61% | 7.75% | 11.07% | 24.05% | Upgrade
|
| Profit Margin | 8.74% | 9.89% | 6.05% | 9.82% | 21.26% | Upgrade
|
| Free Cash Flow Margin | -7.13% | 7.64% | 4.96% | 2.39% | 14.90% | Upgrade
|
| EBITDA | 10,082 | 9,141 | 6,962 | 8,585 | 14,663 | Upgrade
|
| EBITDA Margin | 15.11% | 14.67% | 12.32% | 16.18% | 27.19% | Upgrade
|
| D&A For EBITDA | 2,786 | 2,533 | 2,584 | 2,710 | 1,695 | Upgrade
|
| EBIT | 7,297 | 6,607 | 4,378 | 5,875 | 12,968 | Upgrade
|
| EBIT Margin | 10.94% | 10.61% | 7.75% | 11.07% | 24.05% | Upgrade
|
| Effective Tax Rate | 17.70% | 2.53% | 3.56% | 16.70% | 18.10% | Upgrade
|
| Revenue as Reported | 67,146 | 62,569 | 56,554 | 53,563 | 54,804 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.